Silymarin: A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo

Chi H. Wu, Shang Ming Huang, Gow Chin Yen

研究成果: 雜誌貢獻文章同行評審

54 引文 斯高帕斯(Scopus)


The current study was designed to evaluate the effects of silymarin (SM) on advanced glycation endproduct (AGE) formation and monocyte activation induced by S100b, a specific ligand of receptor for AGEs. The in vivo verification of antiglycation, antioxidant, and antiinflammatory capacities was examined by 12 weeks of SM administration in streptozotocin-diabetic rats. In vitro glycation assays demonstrated that SM exerted marked inhibition during the late stages of glycation and subsequent crosslinking. Dual action mechanisms, namely, antioxidant and reactive carbonyl trapping activities, may contribute to its antiglycation effect. SM produced a significant decrease in monocytic interleukin-1β and COX-2 levels and prevented oxidant formation caused by S100b, which appeared to be mediated by inhibition of p47phox membrane translocation. Chromatin immunoprecipitation demonstrated that S100b increased the recruitment of nuclear factor-kappaB transcription factor as well as cAMP response element-binding-binding protein and coactivator-associated arginine methyltransferase-1 cofactors to the interleukin-1β promoter, whereas these changes were inhibited with SM treatment. In vivo, SM reduced tissue AGE accumulation, tail collagen crosslinking, and concentrations of plasma glycated albumin. Levels of oxidative and inflammatory biomarkers were also significantly decreased in SM-treated groups compared with the diabetic group. These data suggest that SM supplementation may reduce the burden of AGEs in diabetics and may prevent resulting complications.

頁(從 - 到)353-366
期刊Antioxidants and Redox Signaling
出版狀態已發佈 - 二月 1 2011

ASJC Scopus subject areas

  • 生物化學
  • 細胞生物學
  • 臨床生物化學
  • 分子生物學
  • 生理學


深入研究「Silymarin: A novel antioxidant with antiglycation and antiinflammatory properties in vitro and in vivo」主題。共同形成了獨特的指紋。